Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Influenza Vaccine in Melanoma
NCT04697576Phase 1Recruiting
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of influenza virus quadrivalent inactivated vaccine in melanoma (2 cohorts). Primary endpoints: Incidence of adverse events at 1 year and Maximum tolerated dose at 98 days. Started Oct 2021; status: recruiting.
02
Drugs
influenza virus quadrivalent inactivated vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04697576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697576.